X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What they’re saying: Safety is top concern for recent drug importation proposal

By Nicole Longo  |    August 8, 2019
Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan,” which would allow importation of...   Read More

IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle

By Tom Wilbur  |    August 6, 2019
Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell...   Read More

ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals

By Tiffany Haverly  |    August 1, 2019
This week, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced their “Safe Importation Action Plan.” While patients are rightfully concerned about...   Read More

IP Explained: Understanding biopharmaceutical innovation

By Andrew Powaleny  |    July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...   Read More

IP Explained: Why IP protections are important for biologic medicines

By Tom Wilbur  |    July 18, 2019
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing...   Read More

PhRMA member companies invested nearly $80 billion in R&D last year

By Tim McClung  |    July 18, 2019
Last year, PhRMA member companies invested a record-setting $79.6 billion in research and development (R&D) according to the 2019 PhRMA member annual survey.   Read More

Setting the record straight on international reference pricing

By Kevin Haninger  |    July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...   Read More

Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices

By Nick McGee  |    July 15, 2019
West Virginia, Virginia, Arizona and Illinois recently became the first states in America to adopt patient-centered legislation to bring relief and more predictability to patients facing high...   Read More

New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?

By Priscilla VanderVeer  |    July 9, 2019
For the last two years, our Let’s Talk About Cost campaign has sought to answer questions people have about their medicine costs and advance a dialogue on how we can make medicines more affordable...   Read More

Study finds hospitals continue to mark up medicines up to 500% of their cost

By Holly Campbell  |    July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates